Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.52 |
| ▸ | PRCP | P42785 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288260 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL29350565 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL29398238 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL29350888 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL43168 | 1.00 | GAA (0.58) | GAAMAPTMEN1KMT2AEGLN1 | |
| Bromide SCHEMBL8763315 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 | |
| Hydrochloric Acid SCHEMBL7272493 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 | |
| Hydrochloric Acid SCHEMBL1202518 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 | |
| Hydrochloric Acid SCHEMBL32677098 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 | |
| SCHEMBL28412655 | 0.98 | GAA (0.56) | GAAMAPTMEN1KMT2AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-09-04 | — | — | US | claimed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | claimed |
| US-12104106-B2 | Compositions of chiral molecules and perovskite nanocrystals and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2024-10-01 | — | — | US | claimed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | claimed |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | claimed |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | claimed |
| EP-4007635-B1 | COMPOSITIONS COMPRISING CHEMERIN ANALOGS AND METHODS OF USE | OKYO PHARMA LTD (GG) | 2024-06-19 | — | — | EP | claimed |
| CN-117586170-B | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117813313-A | Binding hepcidin mimetics | 领导医疗有限公司 | 2024-04-02 | — | — | CN | claimed |
| EP-1009749-A1 | PREPARATION OF (S)-N-TERT-BUTYL-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYAMIDE | Archimica S.p.A. (IT) | 2000-06-21 | — | — | EP | claimed |
| EP-0992495-A1 | PROCESS FOR OBTAINING QUINAPRYL HYDROCHLORIDE AND SOLVATES USEFUL FOR ISOLATING AND PURIFYING QUINAPRYL HYDROCHLORIDE | ESTEVE QUIMICA, S.A. (ES) | 2000-04-12 | — | — | EP | claimed |
| WO-2000000494-A1 | PREPARATION OF (S)-N-TERT-BUTYL-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYAMIDE | ARCHIMICA S.P.A. (IT) | 2000-01-06 | — | — | WO | claimed |
| EP-0751128-B1 | Process for producing optically active amides | AJINOMOTO KK (JP) | 1999-07-28 | — | — | EP | claimed |
| EP-0902781-A1 | PREPARATION OF (S)-DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID T-BUTYLAMIDE | Monsanto Company (US) | 1999-03-24 | — | — | EP | claimed |
| WO-1997030976-A1 | PREPARATION OF (S)-DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID T-BUTYLAMIDE | MONSANTO COMPANY (US) | 1997-08-28 | — | — | WO | claimed |
| US-5610307-A | Direct isolution of optically pure (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid | THE NUTRA SWEET COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| EP-0751128-A1 | Process for producing optically active amides | Ajinomoto Co., Ltd. (JP) | 1997-01-02 | — | — | EP | claimed |
| US-5587481-A | Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide | THE MONSANTO COMPANY (US) | 1996-12-24 | — | — | US | claimed |
| US-4912221-A | Chiral 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and precursors and preparation thereof | OCCIDENTAL CHEMICAL CORPORATION (US) | 1990-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | GAA 3513/4885MAPT 4701/4885MEN1 161/4885 |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | GAA 811/4885MAPT 3675/4885MEN1 225/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | GAA 2062/4885MAPT 4449/4885MEN1 3191/4885 |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | GAA 875/4885MAPT 3901/4885MEN1 188/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | GAA 3161/4885MAPT 3433/4885MEN1 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.